Mediwound Ltd. revenue by segment MDWD

Annual Quarterly

Mediwound Ltd. splits its revenue into 5 lines in its filings. The largest line in fiscal 2025, which ended Dec 31, 2025 was US at $11.8 million, 69% of the total.

USD in millions. The percent under a figure is the change from the year before.

Line	FY 2025 Dec 31, 2025	FY 2024 Dec 31, 2024	FY 2023 Dec 31, 2023	FY 2022 Dec 31, 2022	FY 2021 Dec 31, 2021	FY 2020 Dec 31, 2020	FY 2019 Dec 31, 2019	FY 2018 Dec 31, 2018	FY 2017 Dec 31, 2017
Revenue	17	20	19	26	24	22	32	3	2
US	12 -23.8% share 69.5%	15 +18.2% share 76.5%	13 -40.2% share 70.0%	22 +20.8% share 82.5%	18 +0.4% share 76.2%	18 -36.7% share 82.8%	29 share 89.7%	—	—
Other Countries	2 -9.4% share 12.2%	2 -12.4% share 11.3%	3 -43.8% share 13.9%	5 -18.3% share 17.5%	6 +51.6% share 23.8%	4 +13.6% share 17.2%	3 share 10.3%	—	—
ES	1 +53.7% share 7.6%	1 -19.4% share 4.2%	1 share 5.6%	—	—	—	—	—	—
IT	1 +22.6% share 5.9%	1 -19.6% share 4.0%	1 share 5.4%	—	—	—	—	—	—
DE	1 -0.8% share 4.8%	1 -13.2% share 4.1%	1 share 5.1%	—	—	—	—	—	—

How these figures are calculated

Annual columns are full-year amounts from the annual report (Form 10-K, 20-F, or 40-F). If a company restates a year, the latest filed number is shown. USD in millions. Each group is a separate split of total revenue, so the groups are not added together. Share of revenue is that line divided by total revenue. More on our methodology.

Company profile

Industry: Medicinal Chemicals & Botanical Products (SIC 2833)
Listed as: MDWD (Nasdaq)
Fiscal year ends: December 31
Incorporated in: Israel
Headquarters: Yavne, Israel
SEC filer status: Accelerated filer
SEC CIK: 1593984

Other Medicinal Chemicals & Botanical Products companies

All 43 Medicinal Chemicals & Botanical Products companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.